The Effects of Chronological Age on the Chondrogenic Potential of Mesenchymal Stromal Cells: A Systematic Review

Int J Mol Sci. 2023 Oct 23;24(20):15494. doi: 10.3390/ijms242015494.

Abstract

Tissue engineering and cell therapy for regenerative medicine have great potential to treat chronic disorders. In musculoskeletal disorders, mesenchymal stromal cells (MSCs) have been identified as a relevant cell type in cell and regenerative strategies due to their multi-lineage potential, although this is likely to be a result of their trophic and immunomodulatory effects on other cells. This PRISMA systematic review aims to assess whether the age of the patient influences the chondrogenic potential of MSCs in regenerative therapy. We identified a total of 3027 studies after performing a search of four databases, including Cochrane, Web of Science, Medline, and PubMed. After applying inclusion and exclusion criteria, a total of 14 papers were identified that were reviewed, assessed, and reported. Cell surface characterization and proliferation, as well as the osteogenic, adipogenic, and chondrogenic differentiation, were investigated as part of the analysis of these studies. Most included studies suggest a clear link between aged donor MSCs and diminished clonogenic and proliferative potential. Our study reveals a heterogeneous and conflicting range of outcomes concerning the chondrogenic, osteogenic, and adipogenic potential of MSCs in relation to age. Further investigations on the in vitro effects of chronological age on the chondrogenic potential of MSCs should follow the outcomes of this systematic review, shedding more light on this complex relationship.

Keywords: MSCs; chondrogenic differentiation; chronological age.

Publication types

  • Systematic Review
  • Review

MeSH terms

  • Adipogenesis
  • Aged
  • Cell Differentiation
  • Cells, Cultured
  • Chondrogenesis
  • Humans
  • Mesenchymal Stem Cells* / metabolism
  • Osteogenesis
  • Tissue Engineering

Grants and funding

The authors gratefully acknowledge the financial support of Evelyn Medical Research Grant (Project Ref: 20-15) as well as of the Versus Arthritis (Formerly Arthritis Research UK) through Versus Arthritis Tissue Engineering and Regenerative Therapies Centre (Grant 21156).